|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
CO-ADMINISTRATION CAN RESULT IN DIMINISHED HYPOTENSIVE AND HYPONATREMIC EFFECTS OF ACE INHIBITORS DUE TO THE EFFECT OF ASPIRIN ON THE RENIN-ANGIOTENSIN CONVERSION PATHWAY
|
THIAZIDE-INDUCED POTASSIUM LOSS MAY CAUSE CARDIAC COMPLICATIONS & POSSIBILITY OF EXCESSIVE REDUCTION IN BLOOD PRESSURE
|
THIAZIDE-INDUCED POTASSIUM LOSS MAY CAUSE CARDIAC COMPLICATIONS & POSSIBILITY OF EXCESSIVE REDUCTION IN BLOOD PRESSURE
|
THIAZIDE-INDUCED POTASSIUM LOSS MAY CAUSE CARDIAC COMPLICATIONS & POSSIBILITY OF EXCESSIVE REDUCTION IN BLOOD PRESSURE
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
AMPHETAMINE MAY REDUCE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING BETABLOCKERS
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT & HYPERKALEMIA
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
CO-ADMINISTRATION WITH OTHER ANTIHYPERTENSIVES MAY RESULT IN ADDITIVE EFFECT OR POTENTIATION
|
POTENTIAL FOR SIGNIFICANT HYPERKALEMIA ; POSSIBILITY OF EXCESSIVE REDUCTION IN BLOOD PRESSURE
|
POTENTIAL FOR SIGNIFICANT HYPERKALEMIA ; POSSIBILITY OF EXCESSIVE REDUCTION IN BLOOD PRESSURE
|
POTENTIAL FOR SIGNIFICANT HYPERKALEMIA ; POSSIBILITY OF EXCESSIVE REDUCTION IN BLOOD PRESSURE
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY IN PATIENTS WHOSE RENAL FUNCTION DEPENDS UPON ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERON SYSTEM EG. PATIENTS WITH SEVERE CHF
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|